EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series

Jingshu Meng, Qiuhui Li, Fang Zhu, Lu Zhou, Xinxiu Liu, Tao Liu, Chunxia Qin, Huaxiong Pan, Baixin Ye, Liling Zhang

MedComm – Oncology · 2026-06 · 5 (2)

DOI: 10.1002/mog2.70077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 04.06.2026. Verfasst von Jingshu Meng und 9 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Meng, J., Li, Q., Zhu, F., Zhou, L., Liu, X., Liu, T., Qin, C., Pan, H., Ye, B., & Zhang, L. (2026). Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series. MedComm – Oncology, 5(2). https://doi.org/10.1002/mog2.70077

Vancouver

Meng J, Li Q, Zhu F, Zhou L, Liu X, Liu T, et al. Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series. MedComm – Oncology. 2026;5(2). doi:10.1002/mog2.70077

BibTeX
@article{Meng2026,
  author = {Meng, Jingshu and Li, Qiuhui and Zhu, Fang and Zhou, Lu and Liu, Xinxiu and Liu, Tao and Qin, Chunxia and Pan, Huaxiong and Ye, Baixin and Zhang, Liling},
  title = {Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series},
  journal = {MedComm – Oncology},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.1002/mog2.70077}
}
Kostenlos starten →